<p>AstraZeneca is still waiting for the go-ahead from the US drug regulator to restart the clinical trial of its potential COVID-19 vaccine in the United States, Chief Executive Pascal Soriot said on Thursday.<br /><br /><strong>Read | <a href="https://www.deccanherald.com/science-and-environment/astrazeneca-under-fire-for-covid-19-vaccine-safety-releases-trial-blueprints-890635.html" target="_blank">AstraZeneca, under fire for Covid-19 vaccine safety, releases trial blueprints</a></strong><br /> </p>.<p>"We are the sponsor of the US study. We then provided all this information to the FDA (U.S. Federal Drug Administration) and we are waiting to hear their decision," Soriot told a virtual World Economic Forum discussion.</p>.<p>The US trial of AstraZeneca's Covid-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the United States have resumed.</p>.<p>US Health and Human Services Secretary Alex Azar said on Wednesday the continued suspension showed the FDA took vaccine safety seriously.</p>.<p>A document posted online by Oxford university last week stated the illness in a British participant that triggered the pause on Sept. 6 may not have been associated with the vaccine.</p>
<p>AstraZeneca is still waiting for the go-ahead from the US drug regulator to restart the clinical trial of its potential COVID-19 vaccine in the United States, Chief Executive Pascal Soriot said on Thursday.<br /><br /><strong>Read | <a href="https://www.deccanherald.com/science-and-environment/astrazeneca-under-fire-for-covid-19-vaccine-safety-releases-trial-blueprints-890635.html" target="_blank">AstraZeneca, under fire for Covid-19 vaccine safety, releases trial blueprints</a></strong><br /> </p>.<p>"We are the sponsor of the US study. We then provided all this information to the FDA (U.S. Federal Drug Administration) and we are waiting to hear their decision," Soriot told a virtual World Economic Forum discussion.</p>.<p>The US trial of AstraZeneca's Covid-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the United States have resumed.</p>.<p>US Health and Human Services Secretary Alex Azar said on Wednesday the continued suspension showed the FDA took vaccine safety seriously.</p>.<p>A document posted online by Oxford university last week stated the illness in a British participant that triggered the pause on Sept. 6 may not have been associated with the vaccine.</p>